Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Blood (2024) 144 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2024-211371

Published: 2024

Journal Articles

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Blood (2024) 144 (Supplement 1): 506.

https://doi.org/10.1182/blood-2024-203338

Published: 2024

Journal Articles

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Mehrdad Abedi, Samer A. Srour, Amandeep Salhotra, Rasmus T. Hoeg, Edmund K. Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, J. Scott McClellan, Nathaniel B. Fernhoff, Everett H. Meyer, Robert Lowsky

Blood (2024) 144 (Supplement 1): 382.

https://doi.org/10.1182/blood-2024-204256

Published: 2024

Journal Articles

Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)

Kunhwa Kim, Auris O Huen, Julia Dai, Rishabh Lohray, Bouthaina S. Dabaja, Jillian R. Gunther, Susan Y. Wu, Carlos P Torres-Cabala, Ranjit Nair, Luis Malpica, Yago Nieto, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Swaminathan P Iyer

Blood (2024) 144 (Supplement 1): 7448.

https://doi.org/10.1182/blood-2024-212007

Published: 2024

Journal Articles

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Yosra M. Aljawai, Rima M. Saliba, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Amanda L. Olson, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Samer A. Srour, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 7442.

https://doi.org/10.1182/blood-2024-210407

Published: 2024

Journal Articles

Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis

Sophiya S Sami, Qaiser Bashir, Neeraj Y. Saini, Yosra M. Aljawai, Chitra Hosing, Uday Popat, Melody R. Becnel, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Samer A. Srour

Blood (2024) 144 (Supplement 1): 1923.

https://doi.org/10.1182/blood-2024-211495

Published: 2024

Journal Articles

Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis

Abdullah Faisal Deen, Qaiser Bashir, Neeraj Y. Saini, Yosra M. Aljawai, Chitra Hosing, Uday Popat, Melody R. Becnel, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash, Samer A. Srour

Blood (2024) 144 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2024-211408

Published: 2024

Journal Articles

Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

Blood (2024) 144 (Supplement 1): 1679.

https://doi.org/10.1182/blood-2024-209213

Published: 2024

Journal Articles

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Blood (2024) 144 (Supplement 1): 695.

https://doi.org/10.1182/blood-2024-200833

Published: 2024

Journal Articles

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Blood (2024) 144 (Supplement 1): 694.

https://doi.org/10.1182/blood-2024-205917

Published: 2024

Journal Articles

Conditioning with Busulfan + Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 7019.

https://doi.org/10.1182/blood-2024-203529

Published: 2024

Journal Articles

Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

Blood (2024) 144 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2024-203404

Published: 2024

Journal Articles

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Blood (2024) 144 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2024-203700

Published: 2024

Journal Articles

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2024-203824

Published: 2024

Journal Articles

Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Jeremy Ramdial, Lorlyn Clemente, Pinaki Banerjee, Bouthaina S. Dabaja, Gheath Al-Atrash, Amin M. Alousi, Betul Oran, Uday Popat, Jin S. Im, Samer A. Srour, George Chen, Partow Kebriaei, Chitra Hosing, David Marin, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin

Blood (2024) 144 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2024-211389

Published: 2024

Journal Articles

Developing a Fit-for-Purpose Composite Symptom Score for Representing Symptom Burden for Managing CRS and Icans after CAR T-Cell Therapy

Xin Shelley Wang, Samer A. Srour, Sattva S. Neelapu, Shu-En Shen, Laila Noor, Sairah Ahmed, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2024-210494

Published: 2024

Journal Articles

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Blood (2023) 142 (Supplement 1): 4962.

https://doi.org/10.1182/blood-2023-174479

Published: 2023

Journal Articles

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4972.

https://doi.org/10.1182/blood-2023-189844

Published: 2023

Journal Articles

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2023-174558

Published: 2023

Journal Articles

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Caspian H. Oliai, Jeremy M. Pantin, Rasmus T. Hoeg, Lori S. Muffly, Sagar S. Patel, Arpita Gandhi, Robert Lowsky, Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, J. Scott McClellan, Mehrdad Abedi, Robert S. Negrin, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 230.

https://doi.org/10.1182/blood-2023-186749

Published: 2023

NARROW

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis

Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis

Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Conditioning with Busulfan + Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis

Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Developing a Fit-for-Purpose Composite Symptom Score for Representing Symptom Burden for Managing CRS and Icans after CAR T-Cell Therapy

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only